Elmind Capital LP Purchases New Stake in Krystal Biotech, Inc. $KRYS

Elmind Capital LP purchased a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 22,000 shares of the company’s stock, valued at approximately $8,176,740,000. Krystal Biotech makes up 2.1% of Elmind Capital LP’s investment portfolio, making the stock its 15th biggest position. Elmind Capital LP owned 0.07% of Krystal Biotech as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. UMB Bank n.a. lifted its stake in shares of Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after buying an additional 37 shares in the last quarter. Optimize Financial Inc grew its holdings in Krystal Biotech by 1.4% during the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock worth $704,000 after buying an additional 40 shares in the last quarter. Regal Investment Advisors LLC grew its stake in shares of Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after acquiring an additional 44 shares in the last quarter. Torray Investment Partners LLC raised its holdings in shares of Krystal Biotech by 0.4% in the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock valued at $3,108,000 after purchasing an additional 47 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund raised its holdings in shares of Krystal Biotech by 0.9% in the first quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company’s stock valued at $1,537,000 after purchasing an additional 53 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

KRYS stock opened at $356.19 on Wednesday. Krystal Biotech, Inc. has a fifty-two week low of $136.73 and a fifty-two week high of $382.54. The stock has a fifty day moving average of $348.02 and a 200-day moving average of $302.59. The company has a market capitalization of $10.54 billion, a price-to-earnings ratio of 44.64 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The firm had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. Equities analysts predict that Krystal Biotech, Inc. will post 7.68 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 51,000 shares of company stock worth $16,278,020. 13.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on KRYS shares. Citigroup boosted their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Evercore reiterated an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Bank of America lifted their target price on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Royal Bank Of Canada began coverage on Krystal Biotech in a research note on Friday, August 14th. They issued an “outperform” rating and a $400.00 target price on the stock. Finally, HC Wainwright upped their target price on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $365.40.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.